Drugmaker GSK shared positive results Monday from two Phase 3 trials testing its inflammatory disease drug depemokimab in people with a condition known as chronic rhinosinusitis with nasal polyps.

UK-based pharmaceutical company GSK has announced positive results from the Phase III ANCHOR-1 and ANCHOR-2 clinical trials of depemokimab in adults with chronic rhinosinusitis with nasal polyps ...